Site icon pharmaceutical daily

Liver Cirrhosis Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Liver
Cirrhosis – Pipeline Review, H1 2019”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Liver Cirrhosis – Pipeline Review, H1 2019, provides comprehensive
information on the therapeutics under development for Liver Cirrhosis
(Gastrointestinal), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological action
of the therapeutics, its complete research and development history and
latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of
key players involved in therapeutic development for Liver Cirrhosis and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase III, Phase II, Phase I,
Preclinical and Discovery stages are 1, 7, 1, 9 and 1 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 1
molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Scope:

Reasons to buy:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/czbg97/liver_cirrhosis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Liver
and Kidney Disorders Drugs

Exit mobile version